开发并鉴定了一个能重现原始肿瘤药物应答和突变特征的结直肠癌 PDX 模型。
Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor.
机构信息
Asan Institute for Life Science, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
Department of Pathology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.
出版信息
Cancer Lett. 2014 Apr 1;345(1):56-64. doi: 10.1016/j.canlet.2013.11.010. Epub 2013 Dec 11.
Cultures of primary tumors are very useful as a personalized screening system for effective therapeutic options. We here describe an effective method of reproducing human primary colon tumors through primary culture and a mouse xenograft model. A total of 199 primary colon tumor cultures were successfully established under optimized conditions to enrich for tumor cells and to expand it for long-term storage in liquid nitrogen. To examine whether these stored cultures retained original tumor properties, fifty primary cultures were xenografted into NOD-SCID mouse. Histological and tumor marker analysis of four representative tumor xenografts revealed that all of the xenograft retained its primary tumor characteristics. Oncomap analysis further showed no change in the major mutations in the xenografts, confirming that our method faithfully reproduced human colon tumors. A drug sensitivity assay revealed that two of the primary cultures were hypersensitive to oxaliplatin rather than 5-FU, which was used in the patients, suggesting it as an effective therapeutic option. We thus present an effective, reproducible preclinical model for testing various personalized therapeutic options in colon cancer patients.
原代肿瘤培养物作为一种有效的治疗选择的个体化筛选系统非常有用。我们在这里描述了一种通过原代培养和小鼠异种移植模型来重现人类原发性结肠肿瘤的有效方法。在优化条件下,共成功建立了 199 个原代结肠肿瘤培养物,以富集肿瘤细胞并进行长期液氮储存。为了检查这些储存的培养物是否保留了原始肿瘤特性,我们将 50 个原代培养物异种移植到 NOD-SCID 小鼠中。对四个代表性肿瘤异种移植的组织学和肿瘤标志物分析表明,所有异种移植均保留了其原发性肿瘤特征。Oncomap 分析进一步显示,异种移植中主要突变没有变化,证实了我们的方法忠实地重现了人类结肠肿瘤。药物敏感性测定显示,两种原代培养物对奥沙利铂而非患者使用的 5-FU 高度敏感,这表明奥沙利铂是一种有效的治疗选择。因此,我们提出了一种有效的、可重现的临床前模型,用于测试结肠癌患者的各种个体化治疗选择。